Lupin Limited has informed the Exchange regarding 'Inspection of U.S. FDA at the Company's Pithampur Unit-3 manufacturing facility'.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Midcap 150 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The U.S. FDA inspected Lupin's Pithampur Unit-3 manufacturing facility from July 7 to July 17, 2025. The inspection concluded with the issuance of a Form-483 containing three observations. The company has stated it will address the observations within the stipulated timeframe and work with the U.S. FDA to resolve them. Lupin reaffirmed its commitment to maintaining CGMP quality standards across all facilities. The disclosure was made under Regulation 30 of the SEBI Listing Regulations.
Form-483 observations are common during FDA inspections and typically do not immediately affect business operations or product approvals, but unresolved observations could lead to further regulatory action. Investors should monitor the company's response and any follow-up communications from the U.S. FDA.